Artificial intelligence method and system for tumor image feature extraction and progression assessment

Abstract

The present application relates to the field of medical observation technology, and in particular to an artificial intelligence method and system for tumor image feature extraction and progression assessment. The method includes: obtaining a tumor detection report and a three-dimensional tumor image; analyzing the three-dimensional tumor image to determine the tumor shrinkage; analyzing the tumor detection report to determine the patient's current state; determining the current tumor state based on the tumor shrinkage and the patient's current state and sending it to the medical staff's equipment so that the medical staff can formulate a treatment plan based on the current tumor state. Reduce the reliance on doctors' experience and subjective judgment, and improve the accuracy and consistency of the evaluation; integrate the three-dimensional tumor images and detection reports to understand the patient's tumor shrinkage and overall health status, provide a more comprehensive basis for formulating personalized treatment plans, and improve treatment effects and patient survival rates; timely adjust the treatment plan by monitoring the tumor shrinkage to avoid the continuation of ineffective treatment.

Description

Technical Field

[0001] The present application relates to the field of medical observation technology, and in particular to an artificial intelligence method and system for tumor image feature extraction and progression assessment. Background Art

[0002] With the development of medical technology, the diagnosis and treatment of tumors have made significant progress. However, the treatment of tumors still faces many challenges. At present, the commonly used treatment methods in clinical practice include surgery, radiotherapy and chemotherapy, but these methods are not always suitable for all patients.

[0003] There are some problems in the implementation of existing tumor treatment methods. First, the evaluation of tumor shrinkage often relies on the doctor's experience and subjective judgment, lacking objective and quantitative evaluation indicators. Second, during tumor treatment, only information such as tumor size and location is paid attention to, without fully considering tumor shrinkage, which may lead to deviations in subsequent diagnosis, affecting or even aggravating the patient's condition. Summary of the invention

[0004] The present application provides an artificial intelligence method and system for tumor image feature extraction and progression assessment to solve the above problems.

[0005] In a first aspect, the present application provides an artificial intelligence method for tumor image feature extraction and progression assessment, the method comprising: Obtain tumor detection reports and three-dimensional tumor images; Analyzing the three-dimensional tumor image to determine tumor shrinkage; Analyze the tumor detection report to determine the patient's current condition; Based on the tumor shrinkage and the patient's current condition, the current tumor status is determined and sent to the medical staff's equipment so that the medical staff can formulate a treatment plan based on the current tumor status.

[0006] Through this program, through computer-assisted image analysis and tumor marker detection, an objective and quantitative evaluation of tumor regression is provided, which reduces the reliance on physician experience and subjective judgment and improves the accuracy and consistency of the evaluation; the comprehensive three-dimensional tumor images and detection reports can fully understand the patient's tumor regression and overall health status, providing a more comprehensive basis for formulating personalized treatment plans; according to the tumor regression and the patient's current status, medical staff can formulate or adjust more accurate treatment plans to improve treatment effects and patient survival rates; through monitoring of tumor regression, the emergence of drug resistance can be identified early, and treatment plans can be adjusted in time to avoid the continuation of ineffective treatment and reduce patients' pain and economic burden; by sending tumor status reports through electronic devices, medical staff can obtain information more conveniently, optimize the allocation of medical resources, and improve the efficiency of medical services.

[0007] Optionally, analyzing the three-dimensional tumor image to determine the tumor shrinkage includes: analyzing the three-dimensional tumor image to determine tumor characteristics; Determining the range to which the tumor belongs according to the tumor characteristics; Determining the tumor volume according to the range to which the tumor belongs; Obtain and analyze historical test reports to determine original tumor information; The tumor shrinkage condition is determined according to the original tumor information and the tumor volume.

[0008] Through this program, by using computer technology and image analysis software, a more objective tumor regression assessment can be provided than the doctor's subjective judgment, subjective errors can be reduced, and the consistency and reliability of the assessment can be improved. It can quantify the changes in tumor volume, provide specific numerical indicators for treatment effects, and help to more accurately monitor the tumor's response to treatment; through continuous volume measurement, signs of tumor regression or progression can be detected earlier, so that treatment plans can be adjusted in time, and detailed tumor characteristics and regression information can be provided to help doctors make more evidence-based treatment decisions. Through accurate assessment of tumor regression, personalized treatment plans can be better implemented and adjusted for specific patient tumor characteristics; because tumor regression can be predicted more accurately, unnecessary repeated examinations and imaging scans may be reduced, saving medical resources.

[0009] Optionally, analyzing the tumor detection report to determine the patient's current status includes: Analyze the tumor detection report to obtain the detection report analysis result, and determine the marker information according to the detection report analysis result; Determining the marker type and the level of each type of marker according to the marker information; Obtaining and analyzing the patient's medical records, and determining the patient's physical immune status based on the results of the case analysis; Determining the impact of each type of tumor marker on the patient based on the body's immune status and the level of each type of marker; The current state of the patient is determined based on the impact.

[0010] Through this program, by analyzing the objective data in the test report, such as the specific values ​​of tumor markers, the uncertainty caused by the doctor's subjective judgment is reduced; combining tumor marker information and the patient's physical immune status, the treatment plan can be formulated or adjusted more accurately to improve the treatment effect; regular analysis of changes in tumor markers helps to monitor the tumor's response to treatment in real time and adjust the treatment strategy in time; by continuously monitoring the marker levels, the recurrence or progression of the tumor can be detected early and corresponding measures can be taken in time; personalized treatment plans are customized according to each patient's tumor markers and immune status to better meet individual needs; overtreatment and unnecessary medical intervention are avoided, and the physical burden on patients is reduced.

[0011] Optionally, determining a treatment plan according to the tumor shrinkage and the patient's current condition includes: Analyzing the tumor characteristics to determine whether a tumor marker is attached to any tumor characteristic; If so, analyzing the tumor detection report and the historical detection report to determine the change level of each type of tumor marker; Based on the case described, determine historical medication use; Determining the patient's physiological drug resistance based on the change level and the historical medication situation; A treatment plan is determined according to the physiological drug resistance and the current condition of the patient.

[0012] Through this program, the uncertainty caused by the doctor's subjective judgment is reduced and the accuracy of the evaluation is improved through quantified tumor marker levels and objective physiological resistance assessment. A personalized treatment plan is formulated according to each patient's tumor characteristics, marker changes, and physiological resistance to better meet the individual needs of patients. Through continuous monitoring of tumor markers and historical medication, the treatment plan can be adjusted in real time to respond to tumor changes and patient tolerance. Considering tumor regression and the patient's current state helps to choose the most effective treatment method and avoid ineffective or excessive treatment. Understanding the patient's physiological resistance can help avoid the use of ineffective treatment methods and reduce the risk of treatment failure and resistance.

[0013] Optionally, determining the patient's physiological drug resistance according to the change level and the historical medication situation includes: Determining blood vessel characteristics around the tumor based on the three-dimensional tumor image; Determining the blood vessel distribution and blood vessel density according to the blood vessel characteristics around the tumor; Determining the effect of blood vessels on tumor markers according to the blood vessel distribution and the blood vessel density; The patient's physiological drug resistance is determined based on the effect of blood vessels on the tumor, the level of change and the historical medication.

[0014] Through this program, by analyzing the change level of tumor markers and historical medication, the patient's physiological resistance can be predicted more accurately, so as to select the most effective treatment method and improve the accuracy of treatment. According to the patient's physiological resistance, a more personalized treatment plan can be formulated, including drug type, dosage, route of administration, etc., to improve the treatment effect. By predicting the patient's physiological resistance, the use of treatment methods that are ineffective for the patient or may have serious side effects can be avoided, reducing the risk of treatment. Accurate treatment plans can improve the patient's survival rate, alleviate symptoms, and improve the quality of life. By predicting the patient's physiological resistance, medical resources can be allocated more reasonably.

[0015] Optionally, determining the effect of each type of tumor marker on the patient according to the body's immune status and the level of each type of marker includes: Determine key immune indicators based on the body's immune status; Determine whether the patient has a genetic factor based on the case analysis results; If so, determine the genetic factor information based on the case analysis results; Determine the patient's living habits and living environment information according to the case analysis results; The influence of each type of tumor marker on the patient is determined based on the genetic factor information, the key immune indexes, the living habits, the living environment information and the level of each type of marker.

[0016] Through this program, by comprehensively analyzing the body's immune status, genetic factor information, lifestyle, living environment information and the level of each type of marker, tumors can be diagnosed more accurately and their possible progression and prognosis can be predicted. According to the patient's immune status and tumor marker levels, a more personalized treatment plan can be formulated, including drug selection, dose adjustment and combination therapy. By analyzing the patient's immune status and tumor marker levels, the use of treatments that are ineffective for the patient or may have serious side effects can be avoided, reducing the risk of treatment.

[0017] Optionally, the influence of each type of tumor marker on the patient is determined based on the genetic factor information, the key immune index, the living habits, the living environment information and the level of each type of marker, and is calculated according to the following formula: ; in, Indicates The impact of a tumor marker on the patient; Indicates The influence weight of each type of tumor marker; Indicates The levels of tumor markers; Indicates The impact weight of the key immune indicators; Indicates key immune indicators; Indicates normal immune index values; Indicates genetic factors; Indicates the genetic factors The influence weight of each tumor marker; Factors representing the living habits and the living environment information; The factors representing the living habits and the living environment information are The influence weight of tumor markers.

[0018] Through this program, through quantitative indicators (such as tumor marker levels, key immune indicators, etc.), the doctor's reliance on subjective judgment is reduced, and the objectivity and accuracy of the evaluation are improved. The formula takes into account a variety of influencing factors, including tumor markers, immune indicators, genetic factors, living habits and living environment, making treatment decisions more comprehensive. Through in-depth analysis of the individual differences of each patient, a more personalized treatment plan can be formulated to improve the treatment effect.

[0019] Optionally, determining the patient's physiological drug resistance based on the effect of blood vessels on the tumor, the change level and the historical medication situation includes: Analyze the historical medication use to determine the types of medication used during the historical period; According to the type of medication, match the historical medication situation to determine the medication frequency of the corresponding type of medication and the dosage of the corresponding type of medication each time; Using a preset simulation model, according to the blood vessel distribution and the blood vessel density, simulating the blood flow state, and determining the angiogenesis index; Determining changes in the comprehensive levels of tumor markers based on the marker information and the historical medication conditions; The physiological drug resistance of the patient is determined according to the medication dosage, the medication frequency, the angiogenesis index, and the level changes of each tumor marker.

[0020] Through this program, tumor regression is evaluated through quantitative indicators (such as angiogenesis index, changes in tumor marker levels, etc.), reducing subjective reliance on physician experience. By analyzing the patient's medication history, angiogenesis, and tumor marker changes, the patient's physiological drug resistance can be more accurately understood, thereby developing a personalized treatment plan. By understanding the patient's physiological drug resistance, drug selection, dosage adjustment, and medication frequency can be optimized to improve treatment efficacy. By monitoring changes in tumor marker levels and angiogenesis index, signs of drug resistance can be detected early and treatment plans can be adjusted in a timely manner.

[0021] Optionally, the physiological drug resistance of the patient is determined based on the medication dosage, the medication frequency, the angiogenesis index, and the comprehensive level change, and is calculated according to the following formula: ; in, Indicates that the patient Physiological resistance to a drug; Indicates the type of drug; represents the angiogenesis index; Indicates the comprehensive level change; Indicates The dosage of the drug at each time of use; Indicates The frequency of use of the drug; represents the weight of the effect of blood vessels on physiological drug resistance; represents the influence weight of the comprehensive level change on physiological drug resistance; It represents the influence weight of the medication frequency on physiological drug resistance.

[0022] Through this program, tumor regression is evaluated through quantitative indicators (such as angiogenesis index, changes in comprehensive levels, medication dosage and frequency), reducing the subjectivity of physician experience and reliance on subjective judgment; the formula takes into account multiple factors, such as angiogenesis, tumor marker changes and medication status, which helps to develop a more personalized treatment plan and improve the effectiveness of treatment. By calculating the physiological resistance index , which can predict a patient's response to a specific drug, thereby helping doctors choose the most appropriate treatment; regular monitoring By monitoring changes in the angiogenesis index, we can track the treatment effect and detect the emergence of drug resistance in time, so as to adjust the treatment plan in time; by considering the angiogenesis index, we can evaluate the density and distribution of blood vessels in the tumor microenvironment, which is crucial for drug delivery. An increase in the angiogenesis index may indicate that it is difficult for drugs to reach tumor cells, leading to drug resistance; consideration of dosage and frequency of medication helps to evaluate the intensity of treatment received by patients, which is crucial for predicting drug resistance and treatment success. The introduction of the power emphasizes the effect of medication frequency on drug resistance, suggesting that frequent low-dose use may lead to drug resistance.

[0023] In a second aspect, the present application provides an artificial intelligence system for tumor image feature extraction and progression assessment, comprising: A data acquisition module, used to obtain tumor detection reports and three-dimensional tumor images; A situation analysis module, used for analyzing the three-dimensional tumor image to determine the tumor shrinkage situation; A report analysis module, used to analyze the tumor detection report and determine the patient's current status; The treatment plan analysis module is used to determine the current tumor status based on the tumor shrinkage and the patient's current status and send it to the medical staff's equipment so that the medical staff can formulate a treatment plan based on the current tumor status.

[0024] Optionally, when the situation analysis module analyzes the three-dimensional tumor image and determines the tumor shrinkage situation, it is used to: analyzing the three-dimensional tumor image to determine tumor characteristics; Determining the scope of the tumor according to the tumor characteristics; Determining the tumor volume according to the range to which the tumor belongs; Obtain and analyze historical test reports to determine original tumor information; The tumor shrinkage condition is determined according to the original tumor information and the tumor volume.

[0025] Optionally, when the report analysis module analyzes the tumor detection report to determine the patient's current status, it is used to: Analyze the tumor detection report to obtain the detection report analysis result, and determine the marker information according to the detection report analysis result; Determining the marker type and the level of each type of marker according to the marker information; Obtaining and analyzing the patient's medical records, and determining the patient's physical immune status based on the results of the case analysis; Determining the impact of each type of tumor marker on the patient based on the body's immune status and the level of each type of marker; The current state of the patient is determined based on the impact.

[0026] Optionally, when determining a treatment plan based on the tumor shrinkage and the patient's current condition, the plan analysis module is used to: Analyzing the tumor characteristics to determine whether a tumor marker is attached to any tumor characteristic; If so, analyzing the tumor detection report and the historical detection report to determine the change level of each type of tumor marker; Based on the case described, determine historical medication use; Determining the patient's physiological drug resistance based on the change level and the historical medication situation; A treatment plan is determined according to the physiological drug resistance and the current condition of the patient.

[0027] Optionally, when the regimen analysis module determines the physiological drug resistance of the patient according to the change level and the historical medication situation, it is used to: Determining blood vessel characteristics around the tumor based on the three-dimensional tumor image; Determining the blood vessel distribution and blood vessel density according to the blood vessel characteristics around the tumor; Determining the effect of blood vessels on tumor markers according to the blood vessel distribution and the blood vessel density; The patient's physiological drug resistance is determined based on the effect of blood vessels on the tumor, the level of change and the historical medication.

[0028] Optionally, when the report analysis module determines the effect of each type of tumor marker on the patient based on the body's immune status and the level of each type of marker, it is used to: Determine key immune indicators based on the body's immune status; Determine whether the patient has a genetic factor based on the case analysis results; If so, determine the genetic factor information based on the case analysis results; Determine the patient's living habits and living environment information according to the case analysis results; The influence of each type of tumor marker on the patient is determined based on the genetic factor information, the key immune indexes, the living habits, the living environment information and the level of each type of marker.

[0029] Optionally, the report analysis module determines the influence of each type of tumor marker on the patient according to the genetic factor information, the key immune index, the living habits, the living environment information and the level of each type of marker, and calculates according to the following formula: ; in, Indicates The impact of a tumor marker on the patient; Indicates The influence weight of each type of tumor marker; Indicates The levels of tumor markers; Indicates The impact weight of the key immune indicators; Indicates key immune indicators; Indicates normal immune index values; Indicates genetic factors; Indicates the genetic factors The influence weight of each tumor marker; Factors representing the living habits and the living environment information; The factors representing the living habits and the living environment information are The influence weight of tumor markers.

[0030] Optionally, when the regimen analysis module determines the patient's physiological drug resistance based on the effect of blood vessels on the tumor, the change level and the historical medication situation, it is used to: Analyze the historical medication use to determine the types of medication used during the historical period; According to the type of medication, match the historical medication situation to determine the medication frequency of the corresponding type of medication and the dosage of the corresponding type of medication each time; Using a preset simulation model, according to the blood vessel distribution and the blood vessel density, simulating the blood flow state, and determining the angiogenesis index; Determining changes in the comprehensive levels of tumor markers based on the marker information and the historical medication conditions; The physiological drug resistance of the patient is determined according to the medication dosage, the medication frequency, the angiogenesis index, and the level changes of each tumor marker.

[0031] Optionally, when the regimen analysis module determines the physiological drug resistance of the patient according to the medication dosage, the medication frequency, the angiogenesis index, and the comprehensive level change, it is calculated according to the following formula: ; in, Indicates that the patient Physiological resistance to a drug; Indicates the type of drug; represents the angiogenesis index; Indicates the comprehensive level change; Indicates The dosage of the drug at each time of use; Indicates The frequency of use of the drug; represents the weight of the effect of blood vessels on physiological drug resistance; represents the influence weight of the comprehensive level change on physiological drug resistance; It represents the influence weight of the medication frequency on physiological drug resistance. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, a brief introduction will be given below to the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative labor.

[0033] Figure 1 A schematic diagram of an application scenario provided for an embodiment of the present application; Figure 2 A flowchart of an artificial intelligence method for tumor image feature extraction and progression assessment provided in one embodiment of the present application; Figure 3 A schematic diagram of the structure of an artificial intelligence system for tumor image feature extraction and progression assessment provided in one embodiment of the present application. DETAILED DESCRIPTION

[0034] In order to make the purpose, technical scheme and advantages of the embodiments of the present application clearer, the technical scheme in the embodiments of the present application will be clearly and completely described below in conjunction with the drawings in the embodiments of the present application. Obviously, the described embodiments are part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.

[0035] In addition, the term "and / or" in this article is only a description of the association relationship of associated objects, indicating that there can be three relationships. For example, A and / or B can represent: A exists alone, A and B exist at the same time, and B exists alone. In addition, the character " / " in this article, unless otherwise specified, generally means that the associated objects before and after are in an "or" relationship.

[0036] The embodiments of the present application are further described in detail below in conjunction with the drawings in the specification.

[0037] There are some problems in the implementation of existing tumor treatment methods. First, the evaluation of tumor shrinkage often relies on the doctor's experience and subjective judgment, lacking objective and quantitative evaluation indicators. Second, during tumor treatment, only information such as tumor size and location is paid attention to, without fully considering tumor shrinkage, which may lead to deviations in subsequent diagnosis, affecting or even aggravating the patient's condition.

[0038] Based on this, the present application provides an artificial intelligence method for tumor image feature extraction and progression assessment, obtains tumor detection reports and three-dimensional tumor images; analyzes three-dimensional tumor images to determine tumor regression; analyzes tumor detection reports to determine the current status of patients; according to the tumor regression and the current status of patients, determines the current tumor status and sends it to the medical staff's equipment, so that medical staff can formulate treatment plans according to the current tumor status. Through computer-assisted image analysis and tumor marker detection, an objective and quantitative evaluation of tumor regression is provided, which reduces the reliance on doctor's experience and subjective judgment, and improves the accuracy and consistency of the evaluation; comprehensive three-dimensional tumor images and detection reports can fully understand the patient's tumor regression and overall health status, and provide a more comprehensive basis for formulating personalized treatment plans; according to the tumor regression and the current status of patients, medical staff can formulate or adjust more accurate treatment plans to improve treatment effects and patient survival rates; through monitoring of tumor regression, the emergence of drug resistance can be identified early, the treatment plan can be adjusted in time, the continuation of ineffective treatment can be avoided, and the pain and economic burden of patients can be reduced; by sending tumor status reports through electronic devices, medical staff can obtain information more conveniently, optimize the allocation of medical resources, and improve the efficiency of medical services.

[0039] Figure 1 A schematic diagram of an application scenario provided for the present application, in which the method provided by the present application is applied during tumor detection. Specifically, the method provided by the present application is applied to any server, and the server interacts with the medical detection system. Through computer-assisted image analysis and tumor marker detection, an objective and quantitative evaluation of tumor regression is provided, which reduces the reliance on physician experience and subjective judgment and improves the accuracy and consistency of the evaluation; comprehensive three-dimensional tumor images and detection reports can fully understand the patient's tumor regression and overall health status, providing a more comprehensive basis for formulating personalized treatment plans; according to the tumor regression and the patient's current condition, medical staff can formulate or adjust more accurate treatment plans.

[0040] For specific implementation methods, please refer to the following embodiments.

[0041] Figure 2 This is a flowchart of an artificial intelligence method for tumor image feature extraction and progression assessment provided in an embodiment of the present application. The method of this embodiment can be applied to the server in the above scenario. Figure 2 As shown, the method includes: S201. Obtain a tumor detection report and a three-dimensional tumor image.

[0042] Tumor detection reports may include laboratory test results, imaging examination results, and the patient's basic information, such as age, gender, medical history, tumor type, etc.

[0043] A three-dimensional tumor image can be generated by computer processing of CT or MRI scan data, which can show the three-dimensional shape, size and relationship of the tumor with surrounding tissues.

[0044] Specifically, the patient's tumor detection report is obtained, and a three-dimensional image of the tumor is obtained through CT or MRI scanning.

[0045] S202: Analyze the three-dimensional tumor image to determine the tumor shrinkage status.

[0046] Tumor regression may specifically refer to changes in tumor volume, changes in tumor marker levels, etc.

[0047] Specifically, computer-aided diagnosis (CAD) software is used to process three-dimensional tumor images, an image segmentation algorithm is used to separate the tumor area from the background, and a volume measurement algorithm is used to calculate the volume change of the tumor to determine tumor shrinkage.

[0048] S203: Analyze the tumor detection report to determine the patient's current condition.

[0049] Specifically, analyze various indicators in the tumor detection report, including tumor marker levels, pathological characteristics, etc.; combine the patient's historical data and clinical information to determine the patient's current status.

[0050] S204. According to the tumor shrinkage and the patient's current condition, determine the current tumor status and send it to the medical staff's equipment so that the medical staff can formulate a treatment plan based on the current tumor status.

[0051] Specifically, the results of the three-dimensional tumor image analysis and tumor detection report analysis are combined to evaluate the tumor shrinkage; the current tumor status is determined based on the tumor shrinkage and the patient's current status. The data on the tumor shrinkage and the patient's current status are integrated to form a comprehensive patient tumor status report; the integrated tumor status report is sent to the medical staff's electronic device, and the medical staff formulates or adjusts the treatment plan based on the received tumor status report combined with clinical experience and professional knowledge.

[0052] Through this program, through computer-assisted image analysis and tumor marker detection, an objective and quantitative evaluation of tumor regression is provided, which reduces the reliance on physician experience and subjective judgment and improves the accuracy and consistency of the evaluation; the comprehensive three-dimensional tumor images and detection reports can fully understand the patient's tumor regression and overall health status, providing a more comprehensive basis for formulating personalized treatment plans; according to the tumor regression and the patient's current status, medical staff can formulate or adjust more accurate treatment plans to improve treatment effects and patient survival rates; through monitoring of tumor regression, the emergence of drug resistance can be identified early, and treatment plans can be adjusted in time to avoid the continuation of ineffective treatment and reduce patients' pain and economic burden; by sending tumor status reports through electronic devices, medical staff can obtain information more conveniently, optimize the allocation of medical resources, and improve the efficiency of medical services.

[0053] In some embodiments, three-dimensional tumor images are analyzed to determine tumor characteristics; based on the tumor characteristics, the range to which the tumor belongs is determined; based on the range to which the tumor belongs, the tumor volume is determined; historical test reports are obtained and analyzed to determine original tumor information; and based on the original tumor information and tumor volume, the tumor regression is determined.

[0054] Tumor regression can be a decrease in the volume or size of the tumor after treatment, such as complete regression, partial regression, or no regression.

[0055] Tumor characteristics can be features such as tumor morphology, size, borders, growth pattern, and histological type.

[0056] The scope of a tumor may refer to the specific location of the tumor in the body, including the organ and site where the tumor is located, the degree of invasion of adjacent tissues or organs, and whether there is distant metastasis.

[0057] Tumor volume can be the size of the tumor, usually expressed as a volume in three-dimensional space, and is obtained by calculating a three-dimensional image of the tumor.

[0058] The original tumor information may be the initial information about the tumor before the patient starts treatment, including the size, location, morphology, stage, grade, histological type, etc. of the tumor.

[0059] Specifically, computer-aided diagnosis (CAD) software is used to process three-dimensional tumor images. Image segmentation algorithms are used to separate tumor areas from the background. Morphological features of the tumor, such as shape, size, and boundary clarity, are analyzed. The specific location and invasion range of the tumor in the body are determined by identifying the boundaries and adjacent structures of the tumor. Three-dimensional reconstruction technology is used to visualize the distribution of the tumor in three-dimensional space. The volume measurement algorithm is used to calculate the volume of the tumor, which is an important indicator for evaluating tumor regression. Tumor volumes at different time points are compared to quantify tumor regression. Historical tumor detection reports of patients, including imaging reports, pathology reports, hematology reports, etc., are collected. These reports are analyzed to obtain the original size, location, histological characteristics, and biological information of the tumor. The current tumor volume is compared with the original tumor volume to calculate the rate of change of the tumor volume. Based on the volume change rate and changes in tumor characteristics, tumor regression is evaluated, including the degree of regression, the speed of regression, and the mode of regression. The above analysis results are integrated into the tumor regression report, including information such as tumor characteristics, the scope of the tumor, volume changes, and the degree of regression. Ensure that the content of the report is accurate and clear, and easy for medical staff to read and understand. The tumor regression report is sent to medical staff through the electronic health record system (EHR) or a dedicated communication platform. Medical staff will formulate or adjust the treatment plan based on the content of the tumor regression report, combined with the patient's overall health status and treatment response. This may include adjusting the drug dosage, changing the treatment plan, or conducting a clinical trial.

[0060] Through this program, by using computer technology and image analysis software, a more objective tumor regression assessment can be provided than the doctor's subjective judgment, subjective errors can be reduced, and the consistency and reliability of the assessment can be improved. It can quantify the changes in tumor volume, provide specific numerical indicators for treatment effects, and help to more accurately monitor the tumor's response to treatment; through continuous volume measurement, signs of tumor regression or progression can be detected earlier, so that treatment plans can be adjusted in time, and detailed tumor characteristics and regression information can be provided to help doctors make more evidence-based treatment decisions. Through accurate assessment of tumor regression, personalized treatment plans can be better implemented and adjusted for specific patient tumor characteristics; because tumor regression can be predicted more accurately, unnecessary repeated examinations and imaging scans may be reduced, saving medical resources.

[0061] In some embodiments, the tumor detection report is analyzed to obtain the detection report analysis results, and the marker information is determined based on the detection report analysis results; the marker type and the level of each type of marker are determined based on the marker information; the patient's case is obtained and analyzed, and the patient's physical immune status is determined based on the case analysis results; based on the physical immune status and the level of each type of marker, the impact of each type of tumor marker on the patient is determined; based on the impact, the patient's current status is determined.

[0062] A tumor detection report can be a record of the results of tumor-related examinations conducted on patients. It usually includes multiple examination results such as imaging examinations (such as CT, MRI, PET-CT, etc.), biochemical examinations (such as blood tumor marker tests), and pathological examinations (such as tissue section examinations).

[0063] The marker information may be specific data about the tumor marker extracted from the tumor detection report, including the name of the marker, the concentration or level, the normal reference range, and whether it exceeds the normal range.

[0064] The marker type can be a classification of the marker based on the biological characteristics and clinical application of the tumor marker.

[0065] A patient's medical record can be a document that records the patient's health status and medical information, including the patient's basic personal information, medical history, physical examination results, laboratory test results, treatment plan, treatment response and follow-up status, etc.

[0066] The body's immune status can refer to the functional state of the patient's immune system, including the number and activity of immune cells, the level of immunoregulatory factors, the intensity and specificity of the immune response, etc.

[0067] Specifically, collect the patient's tumor test reports, including imaging reports, pathology reports, hematology reports, etc. Use natural language processing (NLP) technology or special analysis software to extract key information in the report, such as tumor size, morphology, location, tumor marker levels, etc. Identify the types of tumor markers from the test report, such as CEA, AFP, CA-125, etc. Record the concentration or level of each tumor marker. Classify the tumor markers that appear in the test report and distinguish between benign markers, malignant markers, etc. Count the levels of each type of marker, for example, how many benign markers there are and how many malignant markers there are. Collect the patient's medical history, including medical history, surgical history, treatment history, drug allergy history, etc. Analyze the patient's immune status, including the function of the immune system, the activity of immune cells, and the state of immunosuppression or enhancement. Combine the patient's immune status and the type and number of tumor markers to evaluate the potential impact of each marker on the patient, such as the indication of treatment effect and the progression of the disease. Consider the impact of tumor markers and the patient's immune status, and evaluate the patient's current status, including the severity of the disease, treatment effect, and risk of disease progression. Integrate the analysis results into a detailed patient status report, including marker information, immune status, patient current status, etc.

[0068] Through this program, by analyzing the objective data in the test report, such as the specific values ​​of tumor markers, the uncertainty caused by the doctor's subjective judgment is reduced; combining tumor marker information and the patient's physical immune status, the treatment plan can be formulated or adjusted more accurately to improve the treatment effect; regular analysis of changes in tumor markers helps to monitor the tumor's response to treatment in real time and adjust the treatment strategy in time; by continuously monitoring the marker levels, the recurrence or progression of the tumor can be detected early and corresponding measures can be taken in time; personalized treatment plans are customized according to each patient's tumor markers and immune status to better meet individual needs; overtreatment and unnecessary medical intervention are avoided, and the physical burden on patients is reduced.

[0069] In some embodiments, tumor characteristics are analyzed to determine whether there are tumor markers attached to any of the tumor characteristics; if so, the tumor detection report and historical detection reports are analyzed to determine the change level of each type of tumor marker; based on the case, the historical medication situation is determined; based on the change level and the historical medication situation, the patient's physiological drug resistance is determined; based on the physiological drug resistance and the patient's current condition, a treatment plan is determined.

[0070] Historical medication status may be the history of medications a patient has received in the past.

[0071] Physiological resistance can be a patient's reduced responsiveness to one or more drugs, resulting in the drug being unable to achieve the desired therapeutic effect.

[0072] Specifically, biomarker analysis is performed on the patient's tumor sample to identify potential tumor markers. The expression of tumor markers is detected using methods such as immunohistochemistry, molecular biology techniques, or flow cytometry. Collect and analyze the patient's tumor test reports and historical test reports. Calculate the changes in the concentration or level of each tumor marker and compare the differences before and after treatment or at different time points. Review the patient's medical records to obtain all treatments the patient has received, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Determine detailed information such as the type, dose, and duration of medication used by the patient. Combine the change level of tumor markers and the patient's medication history to assess the patient's sensitivity to specific drugs or treatments. Use drug sensitivity testing and bioinformatics analysis to determine physiological resistance. Assess the size, morphology, and number of tumors through imaging examinations (such as CT, MRI). Use quantitative indicators such as objective response rate (ORR) or complete response rate (CRR) to assess tumor regression. Combine tumor regression, marker changes, physiological resistance, and the patient's overall health status to determine the patient's current status. Consider the following factors: Tumor regression: Tumor regression or stabilization may allow the continuation of current treatment or the trial of a new treatment option. Physiological resistance: If the patient shows physiological resistance, the treatment option may need to be adjusted or changed. The patient's overall health: The treatment option should take into account the patient's age, gender, comorbidities, and tolerance. Treatment goal: The goal of treatment should be to cure, control the disease, relieve symptoms, or improve quality of life. Choose an appropriate treatment option based on the patient's current condition.

[0073] Through this program, the uncertainty caused by the doctor's subjective judgment is reduced and the accuracy of the evaluation is improved through quantified tumor marker levels and objective physiological resistance assessment. A personalized treatment plan is formulated according to each patient's tumor characteristics, marker changes, and physiological resistance to better meet the individual needs of patients. Through continuous monitoring of tumor markers and historical medication, the treatment plan can be adjusted in real time to respond to tumor changes and patient tolerance. Considering tumor regression and the patient's current state helps to choose the most effective treatment method and avoid ineffective or excessive treatment. Understanding the patient's physiological resistance can help avoid the use of ineffective treatment methods and reduce the risk of treatment failure and resistance.

[0074] In some embodiments, the characteristics of the blood vessels around the tumor are determined based on the three-dimensional tumor image; the blood vessel distribution and blood vessel density are determined based on the blood vessel characteristics around the tumor; the effect of the blood vessels on tumor markers is determined based on the blood vessel distribution and blood vessel density; and the patient's physiological drug resistance is determined based on the effect of the blood vessels on the tumor, the level of change and historical medication.

[0075] The peri-tumor blood vessel characteristic may be the growth state of the peri-tumor blood vessels.

[0076] Vascular distribution can be the distribution or structural state of blood vessels in the tumor area, such as uniformity of blood vessel distribution, vascular branching pattern, and vascular network structure.

[0077] The vascular density can be defined as the number of microvessels per unit area of ​​the tumor region.

[0078] Specifically, the three-dimensional image is preprocessed, such as denoising, segmentation, etc., to extract the tumor area. Image analysis technology is used to identify the vascular characteristics around the tumor, including the number of blood vessels, blood vessel diameter, blood vessel density, etc.; image analysis software or algorithms are used to quantify the distribution of blood vessels around the tumor. The blood vessel density is calculated, that is, the number of blood vessels per unit area around the tumor. The uniformity of blood vessel distribution is evaluated to determine the nutritional supply of blood vessels to the tumor. Combined with the level data of tumor markers, the correlation between blood vessels and tumor markers is analyzed. The effect of blood vessels on tumor markers is determined, including whether blood vessels affect the expression or distribution of markers. The patient's historical medication data is collected, including the type of drug, dosage, medication time, and treatment effect. The change level of tumor markers is monitored to understand the tumor's response to treatment. By comparing the patient's tumor marker changes with historical medication, any potential drug resistance patterns are identified; then machine learning or statistical models are used to predict the patient's physiological drug resistance in combination with the patient's clinical characteristics, drug response, and biomarker data, thereby determining the patient's physiological drug resistance to a specific treatment.

[0079] Through this program, by analyzing the change level of tumor markers and historical medication, the patient's physiological resistance can be predicted more accurately, so as to select the most effective treatment method and improve the accuracy of treatment. According to the patient's physiological resistance, a more personalized treatment plan can be formulated, including drug type, dosage, route of administration, etc., to improve the treatment effect. By predicting the patient's physiological resistance, the use of treatment methods that are ineffective for the patient or may have serious side effects can be avoided, reducing the risk of treatment. Accurate treatment plans can improve the patient's survival rate, alleviate symptoms, and improve the quality of life. By predicting the patient's physiological resistance, medical resources can be allocated more reasonably.

[0080] In some embodiments, key immune indicators are determined based on the body's immune status; based on the case analysis results, it is determined whether the patient has genetic factors; if so, the genetic factor information is determined based on the case analysis results; based on the case analysis results, the patient's living habits and living environment information are determined; based on the genetic factor information, key immune indicators, living habits, living environment information and the levels of each type of marker, the impact of each type of tumor marker on the patient is determined.

[0081] Key immune indicators can be biomarkers or indicators used to assess the body's immune status.

[0082] Genetic factors can be the genetic information in an individual's genome that affects tumor growth.

[0083] Specifically, immunological examinations are performed to determine key immune indicators, such as lymphocyte counts, immunoglobulin levels, and T cell subset ratios. The functions of immune cells are analyzed, such as cytotoxic T cell (CTLs) activity and expression of immune checkpoint molecules. Genetic testing and analysis are used to determine whether the patient has tumor-related genetic factors, such as BRCA1 / 2 gene mutations and hereditary non-polyposis colorectal cancer (HNPCC)-related genes. If there are genetic factors, further analyze their specific information, such as mutation type and mutation frequency. Collect information on the patient's living habits, such as eating habits, smoking, drinking, and exercise. Collect information on the patient's living environment, such as the level of pollution in the place of residence and occupational exposure. Detect the level of each type of tumor marker in the patient's blood, urine, or other body fluids, such as alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), etc. Integrate data on immune status, genetic information, living habits, living environment information, and tumor marker levels. Use statistical analysis and bioinformatics tools to analyze the correlation between these data. The impact of each type of tumor marker on patients is evaluated based on the integrated data, the correlation between immune indicators and tumor marker levels, the potential connection between genetic factors and tumor marker levels, the impact of lifestyle habits and living environment on tumor marker levels, and the correlation between tumor marker levels and tumor regression.

[0084] Through this program, by comprehensively analyzing the body's immune status, genetic factor information, lifestyle, living environment information and the level of each type of marker, tumors can be diagnosed more accurately and their possible progression and prognosis can be predicted. According to the patient's immune status and tumor marker levels, a more personalized treatment plan can be formulated, including drug selection, dose adjustment and combination therapy. By analyzing the patient's immune status and tumor marker levels, the use of treatments that are ineffective for the patient or may have serious side effects can be avoided, reducing the risk of treatment.

[0085] In some embodiments, the effect of each type of tumor marker on the patient is determined based on genetic factor information, key immune indicators, lifestyle habits, living environment information, and the level of each type of marker, and is calculated according to the following formula (1): (1) in, Indicates The impact of tumor markers on patients; Indicates The influence weight of each type of tumor marker; Indicates The levels of tumor markers; Indicates The impact weight of the key immune indicators; Indicates key immune indicators; Indicates normal immune index values; Indicates genetic factors; Indicates the genetic factors The influence weight of each tumor marker; Factors that indicate information about living habits and living environment; The factors that indicate the information of living habits and living environment have an impact on the The influence weight of tumor markers.

[0086] Specifically, Calculate tumor markers Initial assessment of impact, is the weight of the tumor marker, indicating its importance to the overall impact, is the level of tumor marker; exponential function Used to amplify or minimize the basal effects of tumor markers; middle Is a key immune indicator The influence weight of is the observed level of immune markers, is the normal level of immune indicators. This ratio is used to measure the abnormality of immune indicators. Logarithmic function Used to normalize the abnormality of immune indicators to make their overall impact smoother; hyperbolic tangent function It is used to compress the calculation results of the immune index impact to between -1 and 1, which helps to control the contribution of the abnormal degree of the immune index to the overall impact and avoid excessive impact of extreme values; : Genetic factors With weight The square of represents the quadratic effect of genetic factors on tumor markers, which may be used to model the strength of genetic tendency. Calculated lifestyle and environmental factors With weight The square root is then taken after multiplication to adjust the contribution of lifestyle and environmental factors to the effects of tumor markers. Multiply it by the index result to get the comprehensive impact index .

[0087] Through this program, through quantitative indicators (such as tumor marker levels, key immune indicators, etc.), the doctor's reliance on subjective judgment is reduced, and the objectivity and accuracy of the evaluation are improved. The formula takes into account a variety of influencing factors, including tumor markers, immune indicators, genetic factors, living habits and living environment, making treatment decisions more comprehensive. Through in-depth analysis of the individual differences of each patient, a more personalized treatment plan can be formulated to improve the treatment effect.

[0088] In some embodiments, historical medication history is analyzed to determine the types of medication used in the historical period; based on the types of medication, historical medication history is matched to determine the frequency of medication of the corresponding type and the dosage of the corresponding type of medication each time; using a preset simulation model, blood flow status is simulated based on vascular distribution and vascular density to determine the angiogenesis index; based on marker information and historical medication history, the comprehensive level changes of tumor markers are determined; based on the dosage, frequency of medication, angiogenesis index, and the level changes of each tumor marker, the patient's physiological drug resistance is determined.

[0089] The preset simulation model may be a mathematical model or a computer model used to simulate processes such as tumor growth, angiogenesis, and blood flow status.

[0090] The angiogenesis index can be an indicator used to quantify the degree of tumor angiogenesis.

[0091] Specifically, analyze the types of medications used by patients in the historical period, including chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, etc. Determine the frequency of use of the corresponding types of drugs and the dosage of each medication. Use the preset simulation model to simulate the blood flow state in the tumor area based on the distribution of blood vessels and vascular density. Calculate the angiogenesis index to quantify the degree of tumor angiogenesis. Collect the patient's tumor marker information, such as CEA, CA-125, PSA, etc. Analyze the changes in the comprehensive level of tumor markers based on historical medication. Comprehensively evaluate the patient's physiological drug resistance based on the dosage, frequency of use, angiogenesis index, and changes in the level of each tumor marker, such as the impact of angiogenesis on drug delivery and drug distribution.

[0092] Through this program, tumor regression is evaluated through quantitative indicators (such as angiogenesis index, changes in tumor marker levels, etc.), reducing subjective reliance on physician experience. By analyzing the patient's medication history, angiogenesis, and tumor marker changes, the patient's physiological drug resistance can be more accurately understood, thereby developing a personalized treatment plan. By understanding the patient's physiological drug resistance, drug selection, dosage adjustment, and medication frequency can be optimized to improve treatment efficacy. By monitoring changes in tumor marker levels and angiogenesis index, signs of drug resistance can be detected early and treatment plans can be adjusted in a timely manner.

[0093] In some embodiments, the physiological drug resistance of the patient is determined based on the dosage, frequency of administration, angiogenesis index, and comprehensive level changes, and is calculated according to the following formula (2): (2) in, Indicates that the patient Physiological resistance to a drug; Indicates the type of drug; represents the angiogenesis index; Indicates changes in the overall level; Indicates The dosage of the drug at each time of use; Indicates The frequency of use of the drug; represents the weight of the effect of blood vessels on physiological drug resistance; It represents the weight of the impact of comprehensive level changes on physiological resistance; Represents the weight of the effect of medication frequency on physiological drug resistance.

[0094] Specifically, : Angiogenesis Index of The power represents the effect of angiogenesis on drug resistance. Angiogenesis is a key process in tumor growth and spread, and the density and distribution of blood vessels can affect drug delivery and nutrient supply to tumor cells. is a weight coefficient indicating the relative importance of angiogenesis in drug resistance. : Overall level changes of The power represents the effect of changes in the levels of tumor markers or other related biomarkers on drug resistance. Changes in these markers may reflect tumor cell proliferation, death, or response to drug treatment. is a weight coefficient indicating the relative importance of these markers in drug resistance. : This is all medicines ( arrive ) dosage and frequency of medication The weighted sum of the products of The power represents the effect of drug frequency on drug resistance, taking into account the potential impact of the intensity and frequency of treatment received by the patient on drug resistance. Adding 1 to the denominator is to avoid the situation where the denominator is zero, thereby ensuring that the drug resistance index is always a positive value.

[0095] Through this program, tumor regression is evaluated through quantitative indicators (such as angiogenesis index, changes in comprehensive levels, medication dosage and frequency), reducing the subjectivity of physician experience and reliance on subjective judgment; the formula takes into account multiple factors, such as angiogenesis, tumor marker changes and medication status, which helps to develop a more personalized treatment plan and improve the effectiveness of treatment. By calculating the physiological resistance index , which can predict a patient's response to a specific drug, thereby helping doctors choose the most appropriate treatment; regular monitoring By monitoring changes in the angiogenesis index, we can track the treatment effect and detect the emergence of drug resistance in time, so as to adjust the treatment plan in time; by considering the angiogenesis index, we can evaluate the density and distribution of blood vessels in the tumor microenvironment, which is crucial for drug delivery. An increase in the angiogenesis index may indicate that it is difficult for drugs to reach tumor cells, leading to drug resistance; consideration of dosage and frequency of medication helps to evaluate the intensity of treatment received by patients, which is crucial for predicting drug resistance and treatment success. The introduction of the power emphasizes the effect of medication frequency on drug resistance, suggesting that frequent low-dose use may lead to drug resistance.

[0096] Figure 3 A schematic diagram of the structure of an artificial intelligence system for tumor image feature extraction and progression assessment provided in one embodiment of the present application is shown in FIG. Figure 3 As shown, the artificial intelligence system 300 for tumor image feature extraction and progression assessment of this embodiment includes: a data acquisition module 301, a situation analysis module 302, a report analysis module 303, and a solution analysis module 304.

[0097] Data acquisition module 301, used to obtain tumor detection reports and three-dimensional tumor images; A situation analysis module 302 is used to analyze the three-dimensional tumor image to determine the tumor shrinkage situation; A report analysis module 303 is used to analyze the tumor detection report and determine the current status of the patient; The treatment plan analysis module 304 is used to determine the current tumor status according to the tumor shrinkage and the current status of the patient and send it to the medical staff's equipment so that the medical staff can formulate a treatment plan according to the current tumor status.

[0098] Optionally, when the situation analysis module 302 analyzes the three-dimensional tumor image and determines the tumor shrinkage situation, it is used to: analyzing the three-dimensional tumor image to determine tumor characteristics; Determining the range to which the tumor belongs according to the tumor characteristics; Determining the tumor volume according to the range to which the tumor belongs; Obtain and analyze historical test reports to determine original tumor information; The tumor shrinkage condition is determined according to the original tumor information and the tumor volume.

[0099] Optionally, when the report analysis module 303 analyzes the tumor detection report to determine the current status of the patient, it is used to: Analyze the tumor detection report to obtain the detection report analysis result, and determine the marker information according to the detection report analysis result; Determining the marker type and the level of each type of marker according to the marker information; Obtaining and analyzing the patient's medical records, and determining the patient's physical immune status based on the results of the case analysis; Determining the impact of each type of tumor marker on the patient based on the body's immune status and the level of each type of marker; The current state of the patient is determined based on the impact.

[0100] Optionally, when determining a treatment plan based on the tumor shrinkage and the patient's current condition, the plan analysis module 304 is used to: Analyzing the tumor characteristics to determine whether a tumor marker is attached to any tumor characteristic; If so, analyzing the tumor detection report and the historical detection report to determine the change level of each type of tumor marker; Based on the case described, determine historical medication use; Determining the patient's physiological drug resistance based on the change level and the historical medication situation; A treatment plan is determined according to the physiological drug resistance and the current condition of the patient.

[0101] Optionally, when the regimen analysis module 304 determines the patient's physiological drug resistance according to the change level and the historical medication situation, it is used to: Determining blood vessel characteristics around the tumor based on the three-dimensional tumor image; Determining the blood vessel distribution and blood vessel density according to the blood vessel characteristics around the tumor; Determining the effect of blood vessels on tumor markers according to the blood vessel distribution and the blood vessel density; The patient's physiological drug resistance is determined based on the effect of blood vessels on the tumor, the level of change and the historical medication.

[0102] Optionally, when determining the effect of each type of tumor marker on the patient according to the body's immune status and the level of each type of marker, the report analysis module 303 is used to: Determine key immune indicators based on the body's immune status; Determine whether the patient has a genetic factor based on the case analysis results; If so, determine the genetic factor information based on the case analysis results; Determine the patient's living habits and living environment information according to the case analysis results; The influence of each type of tumor marker on the patient is determined based on the genetic factor information, the key immune indexes, the living habits, the living environment information and the level of each type of marker.

[0103] Optionally, the report analysis module 303 determines the influence of each type of tumor marker on the patient according to the genetic factor information, the key immune index, the living habits, the living environment information and the level of each type of marker, and calculates according to the following formula: ; in, Indicates The impact of a tumor marker on the patient; Indicates The influence weight of each type of tumor marker; Indicates The levels of tumor markers; Indicates The impact weight of the key immune indicators; Indicates key immune indicators; Indicates normal immune index values; Indicates genetic factors; Indicates the genetic factors The influence weight of each tumor marker; Factors representing the living habits and the living environment information; The factors representing the living habits and the living environment information are The influence weight of tumor markers.

[0104] Optionally, when determining the physiological drug resistance of the patient according to the effect of blood vessels on the tumor, the change level and the historical medication situation, the regimen analysis module 304 is used to: Analyze the historical medication use to determine the types of medication used during the historical period; According to the type of medication, match the historical medication situation to determine the medication frequency of the corresponding type of medication and the dosage of the corresponding type of medication each time; Using a preset simulation model, according to the blood vessel distribution and the blood vessel density, simulating the blood flow state, and determining the angiogenesis index; Determining changes in the comprehensive levels of tumor markers based on the marker information and the historical medication conditions; The physiological drug resistance of the patient is determined according to the medication dosage, the medication frequency, the angiogenesis index, and the level changes of each tumor marker.

[0105] Optionally, when the regimen analysis module 304 determines the physiological drug resistance of the patient according to the medication dosage, the medication frequency, the angiogenesis index, and the comprehensive level change, it is calculated according to the following formula: ; in, Indicates that the patient Physiological resistance to a drug; Indicates the type of drug; represents the angiogenesis index; Indicates the comprehensive level change; Indicates The dosage of the drug at each time of use; Indicates The frequency of use of the drug; represents the weight of the effect of blood vessels on physiological drug resistance; represents the influence weight of the comprehensive level change on physiological drug resistance; It represents the influence weight of the medication frequency on physiological drug resistance.

[0106] The system of this embodiment can be used to execute the method of any of the above embodiments. The implementation principles and technical effects are similar and will not be described in detail here.

Claims

1. An artificial intelligence method for tumor image feature extraction and progression assessment, characterized in that: include: Obtain tumor detection reports and three-dimensional tumor images; Analyzing the three-dimensional tumor image to determine tumor shrinkage; Analyze the tumor detection report to determine the patient's current condition; Based on the tumor shrinkage and the patient's current condition, the current tumor status is determined and sent to the medical staff's equipment so that the medical staff can formulate a treatment plan based on the current tumor status.

2. The method according to claim 1, characterized in that The step of analyzing the three-dimensional tumor image to determine the tumor shrinkage includes: analyzing the three-dimensional tumor image to determine tumor characteristics; Determining the range to which the tumor belongs according to the tumor characteristics; Determining the tumor volume according to the range to which the tumor belongs; Obtain and analyze historical test reports to determine original tumor information; The tumor shrinkage condition is determined according to the original tumor information and the tumor volume.

3. The method according to claim 2, characterized in that The step of analyzing the tumor detection report to determine the current status of the patient includes: Analyze the tumor detection report to obtain the detection report analysis result, and determine the marker information according to the detection report analysis result; Determining the marker type and the level of each type of marker according to the marker information; Obtaining and analyzing the patient's medical records, and determining the patient's physical immune status based on the results of the case analysis; Determining the impact of each type of tumor marker on the patient based on the body's immune status and the level of each type of marker; The current state of the patient is determined based on the impact.

4. The method according to claim 3, characterized in that Determining a treatment plan according to the tumor shrinkage and the patient's current condition includes: Analyzing the tumor characteristics to determine whether a tumor marker is attached to any tumor characteristic; If so, analyzing the tumor detection report and the historical detection report to determine the change level of each type of tumor marker; Based on the case described, determine historical medication use; Determining the patient's physiological drug resistance based on the change level and the historical medication situation; A treatment plan is determined according to the physiological drug resistance and the current condition of the patient.

5. The method according to claim 4, characterized in that Determining the patient's physiological drug resistance according to the change level and the historical medication situation includes: Determining blood vessel characteristics around the tumor based on the three-dimensional tumor image; Determining the blood vessel distribution and blood vessel density according to the blood vessel characteristics around the tumor; Determining the effect of blood vessels on tumor markers according to the blood vessel distribution and the blood vessel density; The patient's physiological drug resistance is determined based on the effect of blood vessels on the tumor, the level of change and the historical medication.

6. The method according to claim 3, characterized in that Determining the effect of each type of tumor marker on the patient according to the body's immune status and the level of each type of marker includes: Determine key immune indicators based on the body's immune status; Determine whether the patient has a genetic factor based on the case analysis results; If so, determine the genetic factor information based on the case analysis results; Determine the patient's living habits and living environment information according to the case analysis results; The influence of each type of tumor marker on the patient is determined based on the genetic factor information, the key immune indexes, the living habits, the living environment information and the level of each type of marker.

7. The method according to claim 6, characterized in that The influence of each type of tumor marker on the patient is determined based on the genetic factor information, the key immune index, the living habits, the living environment information and the level of each type of marker, and is calculated according to the following formula: ； in, Indicates The impact of a tumor marker on the patient; Indicates The influence weight of each type of tumor marker; Indicates The levels of tumor markers; Indicates The impact weight of the key immune indicators; Indicates key immune indicators; Indicates normal immune index values; Indicates genetic factors; Indicates the genetic factors The influence weight of each tumor marker; Factors representing the living habits and the living environment information; The factors representing the living habits and the living environment information are The influence weight of tumor markers.

8. The method according to claim 5, characterized in that Determining the patient's physiological drug resistance based on the effect of blood vessels on the tumor, the change level and the historical medication situation includes: Analyze the historical medication use to determine the types of medication used during the historical period; According to the type of medication, match the historical medication situation to determine the medication frequency of the corresponding type of medication and the dosage of the corresponding type of medication each time; Using a preset simulation model, according to the blood vessel distribution and the blood vessel density, simulating the blood flow state, and determining the angiogenesis index; Determining changes in the comprehensive levels of tumor markers based on the marker information and the historical medication conditions; The physiological drug resistance of the patient is determined according to the medication dosage, the medication frequency, the angiogenesis index, and the level changes of each tumor marker.

9. The method according to claim 8, characterized in that The physiological drug resistance of the patient is determined according to the medication dosage, the medication frequency, the angiogenesis index, and the comprehensive level change, and is calculated according to the following formula: ； in, Indicates that the patient Physiological resistance to a drug; Indicates the type of drug; represents the angiogenesis index; Indicates the comprehensive level change; Indicates The dosage of the drug at each time of use; Indicates The frequency of use of the drug; represents the weight of the effect of blood vessels on physiological drug resistance; represents the influence weight of the comprehensive level change on physiological drug resistance; It represents the influence weight of the medication frequency on physiological drug resistance.

10. An artificial intelligence system for tumor image feature extraction and progression assessment, characterized in that: include: A data acquisition module, used to obtain tumor detection reports and three-dimensional tumor images; A situation analysis module, used for analyzing the three-dimensional tumor image to determine the tumor shrinkage situation; A report analysis module, used to analyze the tumor detection report and determine the patient's current status; The treatment plan analysis module is used to determine the current tumor status based on the tumor shrinkage and the patient's current status and send it to the medical staff's equipment so that the medical staff can formulate a treatment plan based on the current tumor status.

Images